for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Fresenius Says FDA Accepted For Review Kabi's Biologics License Application For Biosimilar MSB11455

May 27 (Reuters) - FRESENIUS SE & CO KGAA:

* FDA ACCEPTED FOR REVIEW COMPANY`S BIOLOGICS LICENSE APPLICATION (BLA) FOR MSB11455, A BIOSIMILAR CANDIDATE OF NEULASTA® (PEGFILGRASTIM) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up